FENNEC PHARMACEUTICALS INC. - Common stock, no par value (the "Shares") (FENC)
CUSIP: 31447P100
Q2 2018 13F Holders as of 30 Jun 2018
- Type / Class
- Equity / Common stock, no par value (the "Shares")
- Shares outstanding
- 34,145,841
- Total 13F shares
- 9,392,799
- Share change
- +1,768,938
- Total reported value
- $98,080,873
- Price per share
- $10.44
- Number of holders
- 43
- Value change
- +$18,177,598
- Number of buys
- 33
- Number of sells
- 6
Quarterly Holders Quick Answers
What is CUSIP 31447P100?
CUSIP 31447P100 identifies FENC - FENNEC PHARMACEUTICALS INC. - Common stock, no par value (the "Shares") in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 31447P100:
Top shareholders of FENC - FENNEC PHARMACEUTICALS INC. - Common stock, no par value (the "Shares") (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Southpoint Capital Advisors LP |
13F
|
Company |
12%
|
3,997,214
|
$48,346,000 | — | 31 Mar 2018 | |
| Opaleye Management Inc. |
13F
|
Company |
2.6%
|
873,000
|
$10,559,000 | — | 31 Mar 2018 | |
| 683 Capital Management, LLC |
13F
|
Company |
2.5%
|
867,185
|
$10,489,000 | — | 31 Mar 2018 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
2.2%
|
741,175
|
$8,961,000 | — | 31 Mar 2018 | |
| Avoro Capital Advisors LLC |
13F
|
Company |
0.8%
|
272,666
|
$3,284,000 | — | 31 Mar 2018 | |
| PUTNAM INVESTMENTS LLC |
13F
|
Company |
0.77%
|
263,433
|
$3,185,000 | — | 31 Mar 2018 | |
| ACUTA CAPITAL PARTNERS, LLC |
13F
|
Company |
0.73%
|
250,000
|
$3,024,000 | — | 31 Mar 2018 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.27%
|
92,658
|
$1,120,000 | — | 31 Mar 2018 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.17%
|
56,707
|
$686,000 | — | 31 Mar 2018 | |
| Granahan Investment Management, LLC |
13F
|
Company |
0.14%
|
47,376
|
$573,000 | — | 31 Mar 2018 | |
| UNITED SERVICES AUTOMOBILE ASSOCIATION |
13F
|
Company |
0.13%
|
45,848
|
$554,000 | — | 31 Mar 2018 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.1%
|
34,800
|
$421,000 | — | 31 Mar 2018 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.08%
|
28,811
|
$348,000 | — | 31 Mar 2018 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.05%
|
17,998
|
$218,000 | — | 31 Mar 2018 | |
| Cardinal Capital Management |
13F
|
Company |
0.04%
|
12,037
|
$145,000 | — | 31 Mar 2018 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.03%
|
11,132
|
$135,000 | — | 31 Mar 2018 | |
| Hartford Financial Management Inc. |
13F
|
Company |
0.03%
|
9,000
|
$108,000 | — | 31 Mar 2018 | |
| MORGAN STANLEY |
13F
|
Company |
0.01%
|
1,866
|
$23,000 | — | 31 Mar 2018 | |
| Edge Wealth Management LLC |
13F
|
Company |
0%
|
502
|
$6,000 | — | 31 Mar 2018 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
82
|
$1,000 | — | 31 Mar 2018 | |
| Federation Des Caisses Desjardins du Quebec |
13F
|
Individual |
0%
|
1
|
$11 | — | 31 Mar 2018 |
Institutional Holders of FENNEC PHARMACEUTICALS INC. - Common stock, no par value (the "Shares") (FENC) as of Q2 2018
As of 30 Jun 2018,
FENNEC PHARMACEUTICALS INC. - Common stock, no par value (the "Shares") (FENC) was held by
43 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
9,392,799 shares.
The largest 10 holders included
Southpoint Capital Advisors LP, venBio Select Advisor LLC, Opaleye Management Inc., 683 Capital Management, LLC, EVENTIDE ASSET MANAGEMENT, LLC, BlackRock Inc., PUTNAM INVESTMENTS LLC, ACUTA CAPITAL PARTNERS, LLC, STATE STREET CORP, and NORTHERN TRUST CORP.
This page lists
43
institutional shareholders reporting positions in this security
for the Q2 2018 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2018 vs Q1 2018 Across Filers
Q1 2018 holders
21
Q2 2018 holders
43
Holder diff
22
| Investor | Q1 2018 Shares | Q2 2018 Shares | Share Diff | Share Chg % | Q1 2018 Value $ | Q2 2018 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.